These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 14692394)

  • 1. Concern about attitude over MMR vaccine.
    Dean S
    Br J Nurs; 2003 Nov 13-26; 12(20):1176. PubMed ID: 14692394
    [No Abstract]   [Full Text] [Related]  

  • 2. Why do parents hesitate to vaccinate their children against measles, mumps and rubella?
    Alfredsson R; Svensson E; Trollfors B; Borres MP
    Acta Paediatr; 2004 Sep; 93(9):1232-7. PubMed ID: 15384890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children.
    Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
    Clin Immunol; 2005 May; 115(2):154-61. PubMed ID: 15885638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
    Spoulou V; Giannaki M; Vounatsou M; Bakoula C; Grafakos S
    Bone Marrow Transplant; 2004 Jun; 33(12):1187-90. PubMed ID: 15077129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immediate injection pain in infants aged 18 months during vaccination against measles, mumps and rubella with either Priorix or MMR-II.
    Knutsson N; Jansson UB; Alm B
    Vaccine; 2006 Jul; 24(31-32):5800-5. PubMed ID: 16765490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Views towards compulsory MMR vaccination in the UK.
    Gardner B; McAteer J; Davies A; Michie S
    Arch Dis Child; 2010 Aug; 95(8):658-9. PubMed ID: 20522456
    [No Abstract]   [Full Text] [Related]  

  • 10. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.
    Davidkin I; Jokinen S; Broman M; Leinikki P; Peltola H
    J Infect Dis; 2008 Apr; 197(7):950-6. PubMed ID: 18419470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the potency and potential immunomodulatory effects of the measles mumps rubella and varicella vaccine in infants.
    Yerkovich ST; Rowe J; Richmond P; Suriyaarachchi D; Heaton T; Hollams E; Ladyman C; Serralha M; Sadowska A; Loh R; Wesselingh SL; Sly PD; Holt PG
    Vaccine; 2007 Feb; 25(10):1764-70. PubMed ID: 17224218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?
    Abbassy AA; Barakat SS; Abd El Fattah MM; Said ZN; El Metwally HA
    East Mediterr Health J; 2009; 15(1):85-93. PubMed ID: 19469430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
    Sultana R; Rahman MM; Hassan Z; Hassan MS
    Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
    Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
    J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
    Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine.
    Vesikari T; Sadzot-Delvaux C; Rentier B; Gershon A
    Pediatr Infect Dis J; 2007 Jul; 26(7):632-8. PubMed ID: 17596807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of MMR-vaccinations and diseases on atopic sensitization and allergic symptoms in Swiss schoolchildren.
    Roost HP; Gassner M; Grize L; Wüthrich B; Sennhauser FH; Varonier HS; Zimmermann H; Braun-Fahrländer Ch;
    Pediatr Allergy Immunol; 2004 Oct; 15(5):401-7. PubMed ID: 15482514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A serological survey of measles, mumps and rubella immunity among school aged children in Western Saudi Arabia.
    Jaber SM
    Saudi Med J; 2006 Jan; 27(1):63-9. PubMed ID: 16432596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: is prevaccination screening cost-effective?
    Celikbas A; Ergonul O; Aksaray S; Tuygun N; Esener H; Tanir G; Eren S; Baykam N; Guvener E; Dokuzoguz B
    Am J Infect Control; 2006 Nov; 34(9):583-7. PubMed ID: 17097453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.